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Abstract We have studied the intracellular localization of 
glycogenin by fusing green fluorescent protein (GFP) to the 
N-terminus of rabbit muscle glycogenin and expressing the 
chimeric protein in C2Ci2, COS-1 and rat hepatic cells. The 
fusion protein showed a nuclear and cytosolic distribution and 
partially co-localized with actin in the cytosol. Disruption of the 
actin cytoskeleton with cytochalasin D led to a change in the 
pattern of green fluorescence, which coincided with that observed 
for the remaining non-depolymerized actin. The distribution of 
the single point mutant K324A was completely uniform and was 
not affected by this drug. These findings indicate that rabbit 
muscle glycogenin binds to actin through the heptapeptide 
321DNIKKKL327, a common motif found in other actin-binding 
proteins, which is located at the C-terminal end of this protein, 
and suggest that the actin cytoskeleton plays an important role in 
glycogen metabolism. 
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1. Introduction 
Glycogenin is an autocatalytic self-glucosylating protein in-
volved in the de novo synthesis of glycogen (for reviews see 
[1,2]). This glucosyltransferase is capable of transferring a 
glucosyl residue from UDP-glucose to the hydroxyl group 
of its own tyrosine 194, and adding the subsequent 1,4-linked 
glucose units to form a linear oligosaccharide up to 11 gluco-
syl residues long [3]. Glucosylated glycogenin acts as the pri-
mer for the biogenesis of glycogen in muscle and in other 
tissues, and serves as the substrate for glycogen synthase [1,2]. 
Glycogenin was first isolated form rabbit skeletal muscle 
[4,5] but, in contrast to what occurs for glycogen synthase, 
it does not appear to present isoforms characteristic of differ-
ent tissues [6-8]. Nevertheless, its relative abundance varies 
greatly from one cell type to another. By Northern blot anal-
ysis, glycogenin mRNA has been shown to be most abundant 
in skeletal and cardiac muscle, also present in lung, brain, 
kidney and testis but barely detectable in liver [7,8]. At the 
protein level, glycogenin is present in a molar ratio of 1:1 with 
glycogen synthase in rabbit skeletal muscle [9], whereas in 
rabbit liver its abundance is 200-fold lower [6]. 
Recently, the subcellular distribution of glycogenin in dif-
ferent tissues has been examined by histochemical techniques. 
In neuronal cells of chicken retina, endogenous glycogenin is 
present in both the cytoplasm and the cell nucleus [10]. In 
contrast, in rat 1 fibroblasts stably overexpressing rabbit 
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muscle glycogenin, the enzyme was only detected diffusely in 
the cytoplasm, and its distribution was found not to be af-
fected by the presence or absence of glucose in the medium 
[11]. 
We have recently shown that in isolated rat hepatocytes, 
glycogen synthase translocates, in response to glucose, from 
a uniform cytosolic distribution to the cell cortex. In this 
movement towards the cell periphery, a marked increase in 
the co-localization of the protein with actin filaments was 
observed [12]. 
Here, we use the intrinsic fluorescence of the Aequoria vic-
toria green fluorescent protein (GFP) [13] to study the sub-
cellular distribution of glycogenin. We constructed a chimeric 
protein by fusing GFP to the ammo-terminal end of rabbit 
muscle glycogenin (GFP/glycogenin), and the localization of 
the fusion protein overexpressed in three different types of 
cells (C2C12, rat hepatocytes and COS-1) was analyzed by 
confocal microscopy. 
The results obtained with this procedure show that glyco-
genin is mainly found in the cytoplasm, partly bound to actin, 
with a minor fraction in the nucleus. This distribution is not 
affected by the presence or absence of glucose in the incuba-
tion medium, but it is altered by disrupting the actin cytoskel-
eton with cytochalasin D. 
2. Materials and methods 
2.1. Plasmid construction 
Standard molecular cloning techniques were used throughout [14]. 
Total RNA, isolated from rabbit skeletal muscle using the RNagents 
total RNA isolation system (Promega), was used to prepare cDNA 
with the RT-PCR kit (Stratagene). Glycogenin cDNA was amplified 
following the supplier's instructions and using the sense primer (Boeh-
ringer Mannheim) GACCATATGACAGATCAGGCCTTTGTGA-
CACTGACC, which contains a Ndel site at the start codon (under-
lined) and 10 codons complementary to amino acids 1-10 of 
glycogenin, and the antisense primer CCCAGCTCTAGATGC-
TAAGTATCAGAAACAAGTGCC, which contains a Xbal site 
(underlined) and is complementary to nucleotides 1098-1133 of the 
3' untranslated region of the rabbit muscle glycogenin cDNA (Gen-
Bank accession number L01791) [7], The PCR product was ligated 
into the Sma\ site of pUC18 using the SureClone ligation kit (Phar-
macia Biotech). The resulting pUC18/glycogenin vector was digested 
with Ndel and blunt-ended with the Klenow fragment of Escherichia 
coli DNA polymerase I and dNTPs (Promega), followed by digestion 
with Sail. The fragment containing the full coding sequence of rabbit 
muscle glycogenin was ligated into pEGFP-Cl (Clontech) which had 
been previously digested with Bglll, Klenow-filled, and digested with 
Sail. This ensured the in-frame fusion of glycogenin at the C-terminus 
of the GFP coding sequence plus a linker of 5 amino acids, under the 
control of the constitutive immediate early promoter of the human 
cytomegalo virus. 
The K324A mutation in the sequence of glycogenin was introduced 
using the QuikChange site-directed mutagenesis kit (Stratagene) and 
the two oligonucleotides CCTTTGACAACATCGCGAAGAAACT-
TGACAC (sense) and GTGTCAAGTTTCTTCGCGATGTTGT-
CAAAGG (antisense), which introduced a Nrul site for diagnostic 
purposes. The final plasmids pEGFP-Cl/glycogenin and pEGFP-Cl/ 
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Fig. 1. Expression of GFP/glycogenin in three different cell types. Confocal images of GFP/glycogenin in C2C12 cells (A), primary cultured hep-
atocytes (D) and COS-1 cells (G). The same population of each cell type labelled with Texas red-conjugated phalloidin: C2Ci2 cells (B), hepa-
tocytes (E) and COS-1 cells (H). Co-localization pixels (where green and red overlap) are shown in white (C, F, I). Scale bar= 10 um. 
K324A-glycogenin were purified by ionic exchange chromatography 
(Qiagen) and finally dissolved in 10 mM Tris-HCl, 0.1 mM EDTA, 
pH 8.0. The DNAs encoding the fusion proteins were sequenced in 
their entirety to confirm the absence of spurious mutations, using the 
ABI-PRISM DNA sequencing kit and the ABI-PRISM 377 automatic 
DNA sequencer (Perkin Elmer Applied Biosystems). 
2.2. Cell culture and transfection 
C2C12 myoblasts (ATCC CRL-1772) were grown on glass cover-
slips in Dulbecco's modified Eagle's medium (DMEM; Whittaker), 
supplemented with 25 mM glucose, 10% fetal bovine serum (FBS; 
Biological Industries) and penicillin/streptomycin (Boehringer Mann-
heim). Differentiation into myotubes was induced by incubating the 
cells in DMEM containing 10% horse serum (HS; Life Technologies) 
instead of FBS. Fused myotubes were observed 3^1 days after the 
medium change [15]. COS-1 cells (ATCC CRL-1650) were grown in 
DMEM supplemented with 25 mM glucose, 10% FBS and penicillin/ 
streptomycin. Liposome-mediated transfection of C2Ci2 and COS-1 
cells was performed at 70-80% confluence, using 4 ug of Clonfectin 
(Clontech) and 4 ug of plasmid DNA per 35 mm dish, following the 
manufacturer's instructions. After transfection (4-5 h) at 37°C in hu-
midified 5% C02:95% air, cells were washed in phosphate-buffered 
saline (PBS) and C2C12 cells were incubated in DMEM supplemented 
with 25 mM glucose and 10% HS. COS-1 cells were incubated in 
DMEM containing 25 mM glucose and 10% FBS. Prior to the experi-
ments, performed 48 h after transfection, both cell types were prein-
cubated for 4-5 h in plain DMEM without glucose. 
Hepatocytes were isolated from 24 h starved male Wistar rats (In-
terfauna) by collagenase perfusion as described [16]. Cells were resus-
pended in DMEM supplemented with 10 mM glucose, 10% FBS, 100 
nM insulin (Sigma), 100 nM dexamethasone (Sigma), and penicillin/ 
streptomycin and seeded (6xl04 cells/cm2) onto gelatin-coated glass 
coverslips placed on tissue culture plates. After 4 h at 37°C in humidi-
fied 5% C02:95% air, unattached cells were removed by washing with 
PBS, and transfection was performed as described above. After trans-
fection, cells were washed in PBS and incubated in plain DMEM 
without glucose for 24 h. On the day of the experiment the three 
cell types were incubated in plain DMEM without glucose (control) 
or with 25 mM glucose and/or 10 nM insulin, for 3 h. 
To disrupt the actin cytoskeleton, cells were incubated for 2 h in 
medium containing cytochalasin D (Sigma), at a concentration of 
1 |xM for C2Ci2 and COS-1 cells and 25 uM for hepatocytes. At the 
end of the incubations, cells were washed twice with PBS, fixed for 20 
min in PBS containing 4% paraformaldehyde and were washed several 
times with PBS. For actin filament staining, fixed cells were incubated 
for 5 min with cold acetone (—20°C), washed extensively with PBS, 
and finally incubated at room temperature for 20 min with Texas red-
conjugated phalloidin (Molecular Probes Europe), diluted 1:50 in 
PBS. Coverslips were air-dried and finally mounted onto glass slides, 
using the Immuno Fluore mounting medium (ICN Biomedicals, Inc.). 
2.3. Confocal microscopy 
Fluorescence images were obtained with a Leica TCS 4D (Leica 
Lasertechnik, Heidelberg, Germany) confocal scanning laser micro-
scope adapted to an inverted Leitz DMIRBE microscope and 63 X 
and 100X (NA 1.4 oil) Leitz Plan-Apo objectives. The light source 
was an argon/krypton laser (75 mW). Green fluorescence (from GFP 
recombinants) and Texas red (used as a marker for actin filaments) 
were excited simultaneously at 488 and 568 nm respectively with the 
laser. Optical sections (0.1 urn) were obtained and co-localization 
analysis was performed with Multicolor software (version 2.0, Leica 
Lasertechnik) as described [17]. The confocal co-localization, defined 
as the topographical overlap of fluorescent markers (GFP (green), and 
Texas red) for the two cellular components, was represented in a 
cytofluorogram, in which the area where the markers overlap was 
indicated in yellow. By image treatment using the confocal system 
to illustrate the sites at which the two proteins co-localized, new 
images were generated in which co-localization is indicated in white. 
3. Results 
3.1. Expression of GFP/glycogenin in muscle cells 
A proportion of C2Q2 cells (5-10%) transfected with the 
pEGFP-Cl/glycogenin construct and incubated in a glucose-
free medium appeared, 2 days after transfection, strongly flu-
orescent. The label was found mainly in the cytosol and also 
in the cell nucleus (Fig. 1A), and no change was observed in 
the subcellular distribution of the chimeric GFP/glycogenin 
protein in the cells incubated with glucose and/or insulin 
(data not shown). Surprisingly, while the control cells trans-
fected with the pEGFP-Cl plasmid, encoding GFP, presented 
uniform diffuse cytosolic and nuclear staining (data not 
shown), the cytosolic fraction of the GFP/glycogenin chimera 
exhibited a mesh-like pattern. When cultured muscle cells 
were stained with Texas red-conjugated phalloidin (Fig. IB), 
a portion of the green fluorescence from the GFP/glycogenin 
fusion protein coincided with actin staining in the same area 
of the cytosol (Fig. 1C). 
3.2. Expression of GFP/glycogenin in rat hepatocytes and 
COS-1 cells 
In order to ascertain whether the observed distribution of 
glycogenin was characteristic of muscle cells or an intrinsic 
property of the protein, we expressed the GFP/glycogenin 
chimera in hepatocytes and COS-1 cells. The efficiency of 
transfection was higher in COS-1 cells (40-50%) than in rat 
hepatocytes (5—10%), but in both cases the transfected cells 
exhibited fluorescent labeling in the cytoplasm and the cell 
nucleus (Fig. 1D,G). As with C2Q2, the subcellular localiza-
tion of glycogenin did not change upon incubation with glu-
cose and/or insulin (data not shown). Again, staining with 
Texas red-conjugated phalloidin indicated that part of the 
cytosolic green label co-localized with red stained actin (Fig. 
1E,F,H,I). 
3.3. Experiments with cytochalasin D 
The treatment of the different cell types used in this study 
with cytochalasin D confirmed the interaction between glyco-
genin and actin in the cytoplasm. While the diffuse uniform 
pattern of fluorescence observed in cells transfected with the 
pEGFP-Cl plasmid was not modified by incubation with this 
drug (data not shown), pEGFP-Cl/glycogenin-transfected 
Fig. 2. Expression of GFP/glycogenin in cells incubated for 2 h in a medium containing cytochalasin D. Confocal images of GFP/glycogenin in 
C2C12 cells (A), primary cultured hepatocytes (D) and COS-1 cells (G). The same population of each cell type labelled with Texas red-conju-
gated phalloidin: C2Ci2 cells (B), hepatocytes (E) and COS-1 cells (H). Co-localization pixels (where green and red overlap) are shown in white 
(C, F, I). Scale bars = 10 urn. 
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cells, when treated with cytochalasin D, showed a dramatic 
change in the green fluorescence pattern. In these conditions, 
the GFP/glycogenin chimera concentrated on the remaining 
non-depolymerized actin (Fig. 2). 
3.4. Expression of the GFPIK324A-glycogenin variant 
An analysis of the sequence of rabbit muscle glycogenin 
revealed the presence of the basic DNIKKKL heptapeptide 
at amino acids 321-327, close to the C-terminal end of the 
enzyme. A similar sequence (DAIKKKL) occurs in cofilin, 
and in other actin-binding proteins [18]. 
To determine whether the 321 DNIKKKL327 heptapeptide is 
responsible for the binding of the enzyme to actin, we pro-
ceeded with a loss of function approach. Lysine 324, the cen-
tral residue of the motif, was replaced by an alanine and the 
GFP/K324A-glycogenin variant was expressed in C2Q2, 
COS-1 cells and cultured hepatocytes. In all cases, the mu-
tated chimeric protein showed a diffuse pattern in the cytosol 
and in the nucleus (data not shown), similar to that exhibited 
by cells transfected with the pEGFP-Cl plasmid. In contrast 
to what was observed for the cells expressing the wild-type 
glycogenin construct (GFP/glycogenin), the pattern of the mu-
tated fusion protein (GFP/K324A-glycogenin) was not altered 
after incubation with cytochalasin D. This shows that the 
interaction between glycogenin and actin is suppressed by 
the single change introduced in the basic DNIKKKL hepta-
peptide, and strongly suggests that this fragment is part of the 
actin-binding site in glycogenin. 
4. Discussion 
We have expressed a GFP/glycogenin fusion protein in 
C2Ci2 and COS-1 cells, and in primary cultured rat hepato-
cytes. In all cases the chimeric fluorescent protein was readily 
detectable by confocal laser microscopy, and mainly localized 
to the cytoplasm of the cells, with a smaller fraction found in 
the nucleus. 
While glycogenin possesses a molecular mass of 37 kDa, 
below the ca. 45 kDa exclusion limit for passive diffusion 
through the nuclear membrane porus [19], the GFP-glycoge-
nin fusion protein has a molecular mass of 64 kDa, well above 
this limit. The detection of fluorescence in the nucleus of the 
cells transiently expressing this construct suggests that glyco-
genin may be actively transported into this cellular compart-
ment. Two recent reports have described the subcellular dis-
tribution of glycogenin in two cell types. Using immuno-
fluorescence techniques, the enzyme was found in the cyto-
plasm and the nucleus of chicken retina cells [10], while 
in rat 1 fibroblasts stably overexpressing rabbit muscle gly-
cogenin, it was detected exclusively in the cytoplasm [11]. 
While we cannot explain these differences, they could be due 
to limitations of the detection technique or to a different be-
havior of this enzyme in various cell types. We have recently 
shown that recombinant muscular glycogen synthase, when 
expressed in C2Q2, COS-1 and rat hepatic cells, concentrates 
in the nucleus under certain metabolic conditions [20]. It has 
also been shown that endogenous glycogen synthase and an 
active synthesis of glycogen both exist in the nucleus of ascites 
tumor cells [21,22]. Therefore, the presence of glycogenin in 
this cellular compartment may be physiologically relevant in 
certain cell types. 
In contrast to what occurs with both known isoforms of 
glycogen synthase, which translocate between different com-
partments in response to glucose [12,20], the subcellular local-
ization of the GFP/glycogenin fusion protein was not altered 
by the presence or the absence of glucose and/or insulin in the 
medium. Interestingly, in both conditions the cytosolic frac-
tion of the GFP/glycogenin fusion protein partly co-localized 
with actin. The interaction between glycogenin and actin has 
been confirmed through the use of cytochalasin D, an actin 
depolymerizing drug. The destructuration of the actin cyto-
skeleton is accompanied by a dramatic change of the cellular 
distribution of the chimeric GFP/glycogenin protein in the 
three cell types studied. All these observations are of special 
interest in the case of the C2Q2 cells, a cell line derived from 
muscle tissue. The relative abundance of glycogenin is much 
greater in muscle cells than in other tissues [7-9]. Native gly-
cogenin isolated from rabbit muscle [23] and from cultured 
quail embryo muscle [24] is phosphorylated. This post-trans-
lational modification, which is induced by insulin [25], has 
been proposed to have a regulatory role [26]. We have not 
observed any significant differences in the cellular localization 
of glycogenin in cells incubated in the presence or absence of 
insulin, suggesting that this hormone does not have an effect 
on the subcellular localization of the enzyme. 
Rabbit muscle glycogenin contains the basic heptapeptide 
DNIKKKL near the C-terminus of the protein, which is 
highly homologous to other sequences present in some ac-
tin-binding proteins. For instance, cofilin contains the 
DAIKKKL sequence [18], DSIKKKL is present in actophor-
in [27], DAIKKKM in tropomyosin [28], DAIKKKF in des-
trin [29] and in the actin depolymerizing factor [30]. Further-
more, actin binds in vitro to the isolated synthetic 
heptapeptide DAIKKKL [31]. Our results indicate that this 
motif in the primary sequence of glycogenin is responsible for 
its binding to actin. The study of the cellular distribution of a 
variant form of the enzyme in which lysine 324 was replaced 
by an alanine residue (K324A-glycogenin) confirmed that the 
mutated enzyme did not interact with actin. In the primary 
sequence of the human skeletal muscle glycogenin, a highly 
homologous fragment (DNIKRKL) can be found, which only 
presents the conservative change of the second lysine residue 
of the motif to an arginine, another basic residue. Although 
the glycogenins from the two different sources exhibit a very 
high degree of identity throughout the entire sequence (93%) 
[8], the conservation of this fragment may indicate its impor-
tance for the function of the enzyme. 
More interestingly, the glucokinases characterized from rat 
[32], mouse [33] and human [34] tissues all contain the 
DAIKRR sequence, again highly homologous to that found 
in actin-binding proteins as well as in glycogenin. Rat gluco-
kinase from liver and islet pancreatic P-cells, overexpressed in 
COS-7 cells, as well as endogenous rat liver glucokinase have 
been shown to co-localize with actin filaments [35]. Further-
more, overexpression of glucokinase, but not of hexokinase I, 
in cultured hepatocytes triggers the activation of glycogen 
synthase and stimulates the synthesis of glycogen [36], sug-
gesting a close interaction between the two enzymes in a com-
mon cellular compartment. Using a similar approach to that 
described here, we are currently investigating the metabolic 
implications of the actin-binding capabilities of glucokinase. 
The translocation of the hepatic glycogen synthase towards 
the cell cortex induced by glucose correlates with a marked 
increase in the co-localization with actin filaments [12]. More-
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over, glycogen synthesis is potently inhibited by cytochalasins 
in cultured rat hepatocytes, by a undefined indirect mecha-
nism that does not involve the covalent inactivation of glyco-
gen synthase. A possible role for the actin cytoskeleton was 
suggested [37]. 
Taken together, all these observations are a clear indication 
of the important role that the actin cytoskeleton plays in the 
metabolism of glycogen, in a yet undefined manner. Fur ther 
studies are required to elucidate the exact role of this cellular 
structure and how it constitutes, probably through the control 
of the cellular localization of the enzymes implicated, an addi-
tional regulatory mechanism of the glycogen synthesis and 
degradation processes. 
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